At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Ruxolitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Topical Ruxolitinib (Jak1/Jak2 Inhibitor) in Chronic Hand Dermatitis Attenuates Inflammation and Enhances Skin Barrier Repair
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib for Chronic Hand Dermatitis. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This is an investigator-initiated, proof of concept, open study to assess efficacy of a topical Ruxolitinib in subjects with Chronic Hand Dermatitis (CHD). The study will be conducted at the University of Rochester Medical center, Dermatology Department - Rochester, NY. Qualified and enrolled subjects (see Inclusion/Exclusion criteria) will be required to come to URMC Dermatology Clinic for at least five visits.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hand Dermatitis
CountriesUnited States
CollaboratorsIncyte Corporation
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartJul 2022
Primary CompletionJun 2023
Study CompletionDec 2024
TodayJul 2026
First PostedMar 24, 2022
Enrollment StartJul 11, 2022
Primary CompletionJun 21, 2023
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.3 years ago
Interventions
Ruxolitinibdrug
1.5% Ruxolitinib cream